Filing Flows › Comparisons › ABCL vs VERA
AbCellera Biologics vs Vera Therapeutics: ABCL and VERA compared
AbCellera Biologics is the larger company: $10.6M of revenue in its latest quarter (Q3 2026) against $10.3M for Vera Therapeutics (Q3 2026). AbCellera Biologics is more profitable, with an operating margin of -501.1% against -931.2%.
Where the money goes: ABCL and VERA
AbCellera Biologics (ABCL) · Q3 2026
AbCellera Biologics, Q3 2026: revenue $10.6M (+19% year over year), operating margin -501.1%, net loss $40.8M, operating cash flow $26.9M. The chart follows the revenue to costs, profit and cash.
Vera Therapeutics (VERA) · Q3 2026
Vera Therapeutics, Q3 2026: revenue $10.3M, operating margin -931.2%, net loss $93.7M, operating cash flow −$99.2M. The chart follows the revenue to costs, profit and cash.
| AbCellera Biologics (ABCL) | Vera Therapeutics (VERA) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $10.6M | $10.3M |
| Revenue growth, Y/Y | +19% | — |
| Operating margin | -501.1% | -931.2% |
| Net earnings | −$40.8M | −$93.7M |
| Net margin | -383.1% | -911.9% |
| Operating cash flow | $26.9M | −$99.2M |
| Free cash flow | $25.3M | — |
| Market value | $3.8B | — |
| Analysts’ mean target | $17.17 | — |
Where the revenue comes from
AbCellera Biologics
- Research fees: $10.5M (99%)
- Licensing and royalty revenue: $90K (1%)
Questions
Which is bigger, AbCellera Biologics or Vera Therapeutics?
AbCellera Biologics is the larger company: $10.6M of revenue in its latest quarter (Q3 2026) against $10.3M for Vera Therapeutics (Q3 2026).
Is AbCellera Biologics or Vera Therapeutics growing faster?
AbCellera Biologics is more profitable, with an operating margin of -501.1% against -931.2%.
More: AbCellera Biologics earnings · how AbCellera Biologics makes money · Vera Therapeutics earnings · how Vera Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 9, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.